The EPS miss and ATM offering create near-term bearish pressure. Monitor for PIVOT-006 topline data as a potential catalyst; a positive readout could offset dilution concerns. The BLA submission timeline (Q4 2026) is a key milestone. The stock may trade on pipeline updates rather than quarterly financials, but the capital raise signals significant cash needs before commercialization.
Drug in focus
CGON drug pipeline →cretostimogene
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
- Next catalyst
- None dated
What to watchWatch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $74.85entry
- T+1 · 3mo ago +0.33%α −0.28% · $75.10
- T+5 · 3mo ago −0.19%α −1.40% · $74.71
- T+20 · 3mo ago −0.69%α −1.29% · $74.33
- T+60 · 18d ago −15.20%α −13.78% · $63.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CG Oncology reported Q2 2026 EPS of -$0.90, significantly wider than the consensus estimate of -$0.64 (a 40.6% miss), with revenue of $1.157M (vs consensus $363K, a 218.7% beat). The net loss widened to $79.1M from $41.4M a year ago, driven by a 74% increase in R&D spend and a 66% increase in G&A costs. The stock is likely to be pressured by the EPS miss and the concurrent $500M ATM equity offering, which signals aggressive funding needs and potential dilution, partially offset by the revenue beat and positive pipeline milestones (PIVOT-006 topline data expected soon, BLA submission in Q4 2026). The company has $1.0B in cash, sufficient through 2029, but the massive capital raise overshadows the near-term outlook.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.90 missed consensus of -$0.64 by 40.6%
- Q2 2026 revenue of $1.157M beat consensus of $363K by 218.7%
- Net loss widened to $79.1M from $41.4M YoY, driven by higher R&D ($54.7M vs $31.3M) and G&A ($29.0M vs $17.4M) expenses
- Cash, cash equivalents and marketable securities at $1.0B, down from $1.1B in Q1 2026; sufficient through 2029
- Concurrent $500M ATM equity offering upsized to $1.05B total, representing potential ~7.8% dilution at current prices
- PIVOT-006 Phase 3 topline data for intermediate-risk NMIBC anticipated near-term; BLA submission for HR BCG-unresponsive NMIBC expected Q4 2026
- BOND-003 Cohort C results published in The Lancet Oncology in July 2026
- Delaware Superior Court upheld jury verdict in favor of CG Oncology in ANI litigation
Financial Impact
Net loss of $79.1M in Q2 2026, EPS miss of $0.26 vs consensus, and a $500M ATM offering creating dilution risk
Risk Factors
- Dilution from the $500M ATM offering could pressure stock price
- Widening net loss and increasing cash burn rate may concern investors
- Clinical trial risks: PIVOT-006 topline data could disappoint
- Regulatory risk: BLA submission and potential FDA approval for cretostimogene are uncertain
- Litigation overhang from ANI dispute, though recent court ruling was favorable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340256 |
Track record
25 reports on CGON
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Viewing Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers